Click here to read more Quest articles. print | Print this page

Identifying Men Susceptible to Prostate Cancer



To facilitate prostate cancer gene mapping and identification, the ICPCG was established in 2002

Dr. Catalona will be a co-investigator for a prostate cancer susceptibility study sponsored by ICPCG, the International Consortium for Prostate Cancer Genetics. (William Isaacs, PhD, Johns Hopkins , Principal Investigator).

Despite prostate cancer being the cancer most commonly diagnosed in men in the U.S., an understanding of the molecular mechanisms underlying susceptibility for prostate cancer remains elusive.

Because of the limited number of samples collected at any single institution, it is difficult to obtain the information necessary to map and identify prostate cancer susceptibility genes.

To facilitate prostate cancer gene mapping and identification, the ICPCG was established in 2002, and Dr. Catalona has collaborated with the ICPCG from its beginning.

This consortium consists of researchers from more than 20 institutions in 7 different countries in North America, Europe and Australia, all of whom have extensive, ongoing research programs in the area of identifying which men are susceptible to prostate cancer and why.

Together, this group has collected DNA samples from more than 1900 prostate cancer families, making their combined resource unique and by far the largest one of its kind. Dr. Catalona will use existing blood/DNA samples collected in the genetic bank at Northwestern University.

Samples with family history and clinical information (but with no identifying names or information) will be sent to the center of ICPCG or the Center for Inherited Disease Research (CIDR) for further laboratory testing and combined data analysis.

Dr. Catalona and his collaborators will also receive testing results and collaborate in the data analysis, presentation of results, and manuscript preparation.

This study is currently funded by the National Cancer Institute and now is under review for refunding.

The collaboration has been ongoing informally and as a NIH-funded consortium for many years, and in recent years, substantial progress is being made.


Close this window